Anticoagulant vs placebo
The review found no eligible studies for this question.
- Pharmacological interventions for asymptomatic carotid stenosis 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether anticoagulant agent changes major bleeding (hospital records/every 6 weeks) compared with placebo (very low certainty).
The review found no eligible studies for this question.
Anticoagulant agent may leads to lower adverse events (hospital records/every 6 weeks) compared with placebo (low certainty).
The review found no eligible studies for this question.
Summary of findings table ‐ Anticoagulant showed no clear difference in dead or dependent at end of compared with control (high certainty).
Summary of findings table ‐ Anticoagulant showed no clear difference in death from all causes during treatment period compared with control (low certainty).
It is very uncertain whether summary of findings table ‐ Anticoagulant changes deep vein thrombosis during treatment period compared with control (very low certainty).
Summary of findings table ‐ Anticoagulant probably leads to lower recurrent ischaemic or unknown stroke during treatment period compared with control (moderate certainty).
Summary of findings table ‐ Anticoagulant probably leads to higher symptomatic intracranial haemorrhage during treatment period compared with control (moderate certainty).
Summary of findings table ‐ Anticoagulant leads to lower symptomatic pulmonary embolism during treatment period compared with control (high certainty).
Summary of findings table ‐ Anticoagulant probably leads to higher major extracranial haemorrhage during treatment period compared with control (moderate certainty).
It is very uncertain whether summary of findings table ‐ Prothrombin complex concentrates changes death or dependence (mRS 4–6) compared with fresh frozen plasma (very low certainty).
It is very uncertain whether summary of findings table ‐ Prothrombin complex concentrates changes intracerebral haemorrhage expansion by 24 hours compared with fresh frozen plasma (very low certainty).
It is very uncertain whether summary of findings table ‐ Prothrombin complex concentrates changes all serious adverse events compared with fresh frozen plasma (very low certainty).
It is very uncertain whether summary of findings table ‐ Prothrombin complex concentrates changes death from any cause compared with fresh frozen plasma (very low certainty).
The review found no eligible studies for this question.